Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal.

• Different epitopes showed different levels of sensitivity to thimerosal treatment. • Reduced conformational stability of HPV antigens in the presence of thimerosal. • Reduced immunogenicity of HPV16 and HPV18 VLPs after thimerosal treatment. • Altered structure of the recombinant HPV18 capsids due to thimerosal treatment. • Thiol modification is likely the basis for structural and functional alterations. Thimerosal has been widely used as a preservative in human vaccines for decades. Thimerosal, a thiol capping agent with ethyl mercury being the active degradant, could have impacts on the vaccine potency due to potential thiol modification. The effects on the antigenicity and immunogenicity of human papillomavirus (HPV) virus-like particles (VLPs) in the presence of thimerosal was studied. In general, reduced binding activity was observed between HPV antigens and monoclonal antibodies (mAbs) upon thimerosal treatment, accompanied by reduced protein conformational stability. The immunogenicity of a pentavalent vaccine formulation (HPV6, HPV11, HPV16, HPV18 and hepatitis E virus) with or without thimerosal was studied in mice. The functional antibody titres, as well as the binding titres, were determined, showing a substantial decrease for vaccine formulations containing thimerosal for HPV16/18. Similarly, epitope-specific competition assays using specific and functional mAbs as tracers also showed a significant reduction in immunogenicity for HPV16/18 in the presence of thimerosal. Structural alterations in the capsid protein for HPV18 were observed with cryo-electron microscopy and 3-dimensional reconstruction in the comparative structural analysis. The results should alert scientists in formulation development field on the choice for vaccine preservatives, in particular for thiol-containing antigens. [ABSTRACT FROM AUTHOR]